New insulin candidate I004 put to the test against NovoLog in healthy volunteers
Knowledge-focused
Recruiting now
This study compares a new rapid-acting insulin (I004) with the approved insulin NovoLog in 60 healthy volunteers. The goal is to see if the new insulin is absorbed and works the same way in the body. Participants receive a single dose of each insulin in random order, and their bl…
Phase: PHASE2, PHASE3 • Sponsor: Amphastar Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 10:11 UTC